CLINICAL AND IMMUNOLOGICAL FEATURES OF THE COURSE OF BRONCHIAL ASTHMA WITH PERSISTENCE OF CYTOMEGALOVIRUS IN CHILDREN

Abstract

Currently, there is a steady increase in the prevalence of bronchial asthma. According to the latest All-Russian medical examination conducted in 2022, the incidence of this disease in ten years in the group of children under 14 years of age has increased more than threefold, and in adolescents over 15 years of age - more than 13 times. In this regard, the treatment of bronchial asthma not only remains a pressing problem in allergology over time, but is also becoming increasingly important. According to modern concepts, bronchial asthma is considered an independent nosological form in which chronic allergic inflammation develops, accompanied by reversible bronchial obstruction and bronchial hyperreactivity. The main mechanism of development of this disease is immunological. Thanks to the achievements of modern pharmacology and allergology, significant progress has been made in the treatment of the main pathological process of bronchial asthma. Over the past decades, the level of relative mortality from bronchial asthma has significantly decreased, the quality of life of patients has improved, and a multiple reduction in the incidence of severe forms of the disease has been achieved.
In recent years, standard international diagnostic criteria and drug therapy methods have been developed that can significantly increase the effectiveness of treatment for patients with bronchial asthma (BA) and improve the quality of life of patients. However, modern drug therapy and monitoring of BA in pregnant women is a more complex task, since it aims not only to preserve the health of the mother, but also to prevent the adverse effects of disease complications and side effects of treatment on the fetus.